###begin article-title 0
Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms
###end article-title 0
###begin p 1
###xml 242 250 <span type="species:ncbi:9606">patients</span>
The cornerstone of pharmacotherapy for OCD is serotonin reuptake inhibition, either with clomipramine or with selective serotonin reuptake inhibitors (SSRIs). In spite of the success of serotonin reuptake inhibiting drugs, nearly half of OCD patients do not respond to treatment. Treatment response may be affected by genetic polymorphisms of the P450 metabolic system. The four most common enzyme-activity reducing polymorphisms of the P450 CYP2D6 enzyme were determined in 91 outpatients with primary OCD according to DSM-IV criteria, receiving dosages titrated upward to 300 mg/day of venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule. Our results show that the investigated CYP2D6 polymorphisms are not a decisive factor in the response to paroxetine and venlafaxine treatment in OCD in spite of their highly significant effect on the blood levels of these medicines.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 1001 1002 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 896 904 <span type="species:ncbi:9606">patients</span>
Serotonin reuptake inhibitors (SRIs) are the most effective pharmacological treatment currently available for patients with obsessive-compulsive disorder (OCD). Still, up to 40-60% of OCD patients do not respond to SRI treatment [1]. We recently reported the pharmacogenetic effect of the 44-bp insertion/deletion 5-HTTLPR polymorphism and the 5-HT2A 1438G/A polymorphism in serotonin-related genes on the efficacy of venlafaxine and paroxetine treatment of OCD [2]. Our findings suggest that these polymorphisms influence the pharmacodynamics of venlafaxine and paroxetine. Polymorphisms in the P450 CYP2D6 enzyme are known to change the pharmacokinetics of venlafaxine and paroxetine [3]. In an effort to characterize whether this pharmacokinetic factor influences the response to paroxetine or venlafaxine treatment, we determined four common polymorphisms of the P450 CYP2D6 enzyme in 91 OCD patients. We investigated the effect of the studied polymorphisms on the blood levels of paroxetine and (O-desmethyl)venlafaxine and on the response to paroxetine treatment or venlafaxine treatment.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 652 660 <span type="species:ncbi:9606">Patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 1326 1334 <span type="species:ncbi:9606">patients</span>
###xml 1515 1523 <span type="species:ncbi:9606">patients</span>
Ninety-one outpatients gave written informed consent for participation in this study, which had been approved by the University of Utrecht Medical Ethical Review committee (Utrecht, The Netherlands). The studied population is described in detail by Denys et al. [2]. Severity of obsessive-compulsive symptoms was rated with the Yale-Brown Obsessive Compulsive Scale (YBOCS), depressive symptoms with the Hamilton Rating scale for Depression (HAM-D) and anxiety with the Hamilton Rating Scale for Anxiety (HAM-A). Only patients with a score of at least 18 on the YBOCS, or at least 12 if only obsessions or only compulsions were present, were included. Patients with a major depressive disorder or patients with a total score of 15 or more on the 17-item HAM-D on admission were excluded. Other exclusion criteria were diagnoses of major depression, bipolar disorder, schizophrenia, other psychotic conditions, substance related disorder within the last 6 months, primary anxiety disorders, personality disorders, use of a concomitant psychotropic drug, organic mental disorders, epilepsy and any structural central nervous system disorder. Furthermore, clinically significant cardiovascular, gastrointestinal, pulmonary, renal, hepatic, endocrine or hematological conditions resulted in exclusion from this study. Of these 91 patients, 17 dropped out of this study because of lack of motivation, uncertain medication use or failure to collect blood for determination of drug plasma concentrations. The 74 remaining patients have following characteristics: 39.2% male; positive family history, 36.1%; age at onset, 19.5 +/- 9.0; age at admission to study, 36.3 +/- 11.6; baseline YBOCS score, 25.0 +/- 5.7.
###end p 5
###begin p 6
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
The patients were randomly assigned in a 12-week, double-blind trial to receive dosages titrated upward to 300 mg/day of venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule. (see Denys et al. [4] for details on the dosing schedule). The patients received no additional drugs affecting the P450 enzyme system and were treatment free at baseline for at least 1 month. Primary efficacy was assessed by the change from baseline on the YBOCS, and response was defined as a >/=25% reduction on the YBOCS.
###end p 6
###begin p 7
###xml 118 119 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 262 263 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
Blood samples were collected from each subject and frozen at -80degreesC. Blood levels of paroxetine, venlafaxine and O-desmethylvenlafaxine were determined at weeks 0, 1, 3, 5, 8, 10 and 12 by high-performance liquid chromatography with fluorescence detection [5]. Blood for the drug level determinations was collected at the response assessment in those weeks, at a random time point after ingestion of the medicine.
###end p 7
###begin p 8
###xml 305 306 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 390 391 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 537 538 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 633 634 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 795 796 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 797 799 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
DNA was extracted from 10 mul of peripheral blood according to standard procedures. The samples were genotyped using TaqMan(R) Drug Metabolism Genotyping Assays from Applied Biosystems for the NCBI dbSNP identification numbers rs3892097 (1846G > A polymorphism, resulting in the inactive CYP2D6 allele 4 [6]), rs5030655 (1707T > Del polymorphism, resulting in the inactive CYP2D6 allele 6 [6]), rs1065852 (100C > T polymorphism, resulting in the reduced activity CYP2D6 allele 10 when not in combination with the 1846G > A polymorphism [7]) and rs28371725 (2988G > A polymorphism, resulting in the reduced activity CYP2D6 allele 41 [8]. In a Caucasian population, the frequency of all inactive and all reduced activity alleles is about 35%, of which 80-90% are caused by the four analyzed SNPs [9,10].
###end p 8
###begin title 9
Results
###end title 9
###begin p 10
###xml 291 299 <span type="species:ncbi:9606">patients</span>
The measured minor allele frequencies for rs3892097, rs5030655, rs1065852, and rs28371725 are 0.24, 0.02, 0.26 and 0.08, respectively. This is in accordance with the minor allele frequencies reported by Applied Biosystems: 0.20, 0.00, 0.21 and 0.11, respectively. Fifty-seven percent of the patients have at least one reduced activity CYP2D6 allele while 13% have two reduced activity CYP2D6 alleles.
###end p 10
###begin p 11
###xml 176 183 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table I</xref>
###xml 308 309 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 485 486 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 631 632 631 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 662 663 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 707 708 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 738 739 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
###xml 761 769 <span type="species:ncbi:9606">patients</span>
To assess the effect of the polymorphisms on the medication plasma levels, all 6 measurements were averaged and two-tailed T-test statistics was performed on this average (see Table I). Paroxetine-treated patients with at least one reduced activity CYP2D6 allele show significantly higher paroxetine levels (P = 0.037) compared to patients with normal alleles. Venlafaxine-treated patients with at least one reduced activity CYP2D6 allele show significantly higher venlafaxine levels (P = 0.018) compared to patients with normal alleles. When considering the venlafaxine metabolites, insignificant differences are found with lower O-desmethylvenlafaxine levels (P = 0.397) and higher combined venlafaxine + O-desmethylvenlafaxine levels (P = 0.065) compared to patients with normal alleles.
###end p 11
###begin p 12
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Plasma levels and response in patients with at least one reduced activity CYP2D6 allele (poor metabolizers) versus patients with only normal alleles.
###end p 12
###begin p 13
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 307 308 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 326 327 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 357 358 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 402 403 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 433 434 433 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">Patients</span>
###xml 456 464 <span type="species:ncbi:9606">patients</span>
In patients with two reduced activity CYP2D6 alleles, the same results are found but with a higher statistical significance level. The plasma metabolite levels also differ significantly. Patients with two reduced activity CYP2D6 alleles show higher paroxetine levels (P = 0.036), higher venlafaxine levels (P < 0.0005), lower O-desmethylvenlafaxine levels (P = 0.017) and higher combined venlafaxine + O-desmethylvenlafaxine levels (P = 0.007) compared to patients with normal alleles.
###end p 13
###begin p 14
###xml 394 400 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 435 442 435 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table I</xref>
###xml 573 579 573 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 715 716 715 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">w</italic>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 580 588 <span type="species:ncbi:9606">patients</span>
In contrast with these findings, the allele frequencies of the individual polymorphisms are almost identical (data not shown) in the responders and non-responders both for the paroxetine group and the venlafaxine group. Pearson chi-square statistics show no significant differences when comparing venlafaxine and paroxetine response in patients with at least one reduced activity CYP2D6 allele versus patients with normal alleles (see Table I). Additionally, no significant differences could be found comparing response in patients with two reduced activity CYP2D6 alleles versus patients with normal alleles. In the studied population, these Pearson chi-square tests have a post-hoc power to detect an effect size w = 0.5 of 0.84.
###end p 14
###begin title 15
Discussion
###end title 15
###begin p 16
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 339 346 <span type="species:ncbi:9606">patient</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
This is the first study assessing the direct impact of CYP2D6 polymorphisms on pharmacological treatment outcome in OCD. Because CYP2D6 duplications (resulting in ultra-rapid metabolizers) and the non-tested CYP2D6 polymorphisms are too uncommon to be studied in a population of 91 patients, these polymorphisms were not analyzed. Because patient subgroups based on individual genotypes are too small to perform useful statistical tests in the studied population, the patients were divided in groups with no, at least one or at least two reduced activity alleles.
###end p 16
###begin p 17
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 1027 1029 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
From the results, we conclude that the investigated CYP2D6 polymorphisms are not a decisive factor in the response to paroxetine and venlafaxine treatment in OCD in spite of their highly significant effect on the blood levels of these medicines. Because of a previously reported lack of effect of paroxetine and venlafaxine blood levels on YBOCS response [4], it is expected that the CYP2D6 polymorphisms do not have a major influence on the response. This lack of relationship drug plasma levels and YBOCS response has also been reported for clomipramine, fluoxetine, fluvoxamine and sertraline [11]. On the other hand, a few studies report on a dose-response relationship: A larger study observed higher venlafaxine blood levels in responders compared to non-responders, but found no evidence for a relationship between treatment outcome and blood levels of paroxetine [12]. Hollander et al reported that paroxetine doses of 40 and 60 mg/day (but not 20 mg/day) are effective in treating acute obsessive-compulsive disorder [13]. Yaryura-Tobias et al indicate that doses of venlafaxine less than 225 mg/day are not effective in OCD [14]. Dose-response studies of paroxetine and/or venlafaxine in OCD treatment are scarce. The results in this study show additional evidence that blood concentrations are not a major factor in the response to venlafaxine and paroxetine treatment of OCD.
###end p 17
###begin p 18
Given the fact that venlafaxine and paroxetine are metabolized primarily by the CYP2D6 enzymes given the fact that the most common reduced activity alleles do not have a major effect on response and given the fact that other CYP2D6 polymorphisms are rare, previous and future studies on response to venlafaxine and paroxetine treatment in OCD are unlikely to be confounded by CYP2D6 polymorphisms.
###end p 18
###begin title 19
Key points
###end title 19
###begin p 20
The four most common enzyme-activity reducing polymorphisms of the P450 CYP2D6 enzyme were determined in 91 outpatients with primary OCD.
###end p 20
###begin p 21
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients received dosages titrated upward to 300 mg/day of venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule.
###end p 21
###begin p 22
The investigated CYP2D6 polymorphisms are not a decisive factor in the response to treatment in spite of their highly significant effect on the blood levels of these medicines.
###end p 22
###begin p 23
None.
###end p 23
###begin title 24
Statement of Interest
###end title 24
###begin p 25
The authors do not have any conflict of interest to report regarding this study.
###end p 25
###begin title 26
References
###end title 26
###begin article-title 27
Biologic approaches to treatment-refractory obsessive-compulsive disorder
###end article-title 27
###begin article-title 28
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial
###end article-title 28
###begin article-title 29
Cyp2d6 and cyp2c19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages
###end article-title 29
###begin article-title 30
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder
###end article-title 30
###begin article-title 31
###xml 121 126 <span type="species:ncbi:9606">human</span>
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum
###end article-title 31
###begin article-title 32
Polymorphism of the cytochrome p450 cyp2d6 gene in a european population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
###end article-title 32
###begin article-title 33
Genetic-analysis of the chinese cytochrome p4502d locus - characterization of variant cyp2d6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
###end article-title 33
###begin article-title 34
A novel intronic mutation, 2988g > a, with high predictivity for impaired function of cytochrome p450 2d6 in white subjects
###end article-title 34
###begin article-title 35
Genetic variation in eleven phase i drug metabolism genes in an ethnically diverse population
###end article-title 35
###begin article-title 36
Cyp2d6 allele frequency in european caucasians, asians, africans and their descendants
###end article-title 36
###begin article-title 37
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Practice guideline for the treatment of patients with obsessive-compulsive disorder
###end article-title 37
###begin article-title 38
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder
###end article-title 38
###begin article-title 39
Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine
###end article-title 39
###begin article-title 40
Venlafaxine in obsessive-compulsive disorder
###end article-title 40

